{"symbol": "LLY", "publishedDate": "2021-10-19 06:45:00", "publisher": "PRNewsWire", "title": "Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk", "image": "https://images.financialmodelingprep.com/news/tirzepatide-results-published-in-the-lancet-show-superior-a1c-20211019.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Oct. 19, 2021 /PRNewswire/ -- Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from Eli Lilly and Company's (NYSE: LLY) SURPASS-4 clinical trial, which were published today in The Lancet . At 52 weeks, the highest dose of tirzepatide led to an A1C reduction of 2.58 percent and reduced body weight by 11.7 kg (-25.8 lb.", "url": "https://www.prnewswire.com/news-releases/tirzepatide-results-published-in-the-lancet-show-superior-a1c-and-body-weight-reductions-compared-to-insulin-glargine-in-adults-with-type-2-diabetes-with-increased-cardiovascular-risk-301402843.html", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-19T06:45:00-04:00", "date_et": "2021-10-19"}
{"symbol": "LLY", "publishedDate": "2021-10-19 15:10:23", "publisher": "Benzinga", "title": "3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat", "image": "https://images.financialmodelingprep.com/news/3-biopharma-stocks-to-watch-following-johnson-johnsons-earnings-20211019.jpg", "site": "benzinga.com", "text": "Johnson & Johnson (NYSE:JNJ) shares are higher Tuesday following the release of its third-quarter results. J&J A Bellwether For The Sector: Given the timing of J&J's earnings release and its portfolio breadth, its earnings often serve as a bellwether for the sector, according to BofA Securities analyst Geoff Meacham.", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/21/10/23443010/3-biopharma-stocks-to-watch-following-johnson-johnsons-earnings-beat", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-19T15:10:23-04:00", "date_et": "2021-10-19"}
{"symbol": "LLY", "publishedDate": "2021-10-20 07:10:00", "publisher": "The Motley Fool", "title": "2 Stocks That Could Grow Your Portfolio Over the Next Decade", "image": "https://images.financialmodelingprep.com/news/2-stocks-that-could-grow-your-portfolio-over-the-20211020.jpg", "site": "fool.com", "text": "These reliable healthcare companies have a lot to offer investors.", "url": "https://www.fool.com/investing/2021/10/20/2-stocks-that-could-grow-your-portfolio-over-the-n/", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-20T07:10:00-04:00", "date_et": "2021-10-20"}
{"symbol": "LLY", "publishedDate": "2021-10-21 06:40:00", "publisher": "The Motley Fool", "title": "Could This Be the Next Blockbuster Indication for Eli Lilly?", "image": "https://images.financialmodelingprep.com/news/could-this-be-the-next-blockbuster-indication-for-eli-20211021.jpg", "site": "fool.com", "text": "Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata.", "url": "https://www.fool.com/investing/2021/10/21/is-this-eli-lillys-next-blockbuster-indication/", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-21T06:40:00-04:00", "date_et": "2021-10-21"}
{"symbol": "LLY", "publishedDate": "2021-10-21 09:25:00", "publisher": "The Motley Fool", "title": "If I Could Only Own 1 Healthcare Stock, This Is What It Would Be", "image": "https://images.financialmodelingprep.com/news/if-i-could-only-own-1-healthcare-stock-this-20211021.jpg", "site": "fool.com", "text": "Investing gets simple if you have to put all of your eggs in one basket.", "url": "https://www.fool.com/investing/2021/10/21/if-i-could-only-own-1-healthcare-stock-this-is-it/", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-21T09:25:00-04:00", "date_et": "2021-10-21"}
{"symbol": "LLY", "publishedDate": "2021-10-21 10:11:28", "publisher": "Zacks Investment Research", "title": "Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?", "image": "https://images.financialmodelingprep.com/news/will-eli-lilly-lly-surpass-q3-earnings-expectations-20211021.jpg", "site": "zacks.com", "text": "Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.", "url": "https://www.zacks.com/stock/news/1813889/will-eli-lilly-lly-surpass-q3-earnings-expectations", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-21T10:11:28-04:00", "date_et": "2021-10-21"}
{"symbol": "LLY", "publishedDate": "2021-10-26 06:25:00", "publisher": "PRNewsWire", "title": "Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential", "image": "https://images.financialmodelingprep.com/news/lilly-reports-robust-thirdquarter-2021-financial-results-as-pipeline-20211026.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Oct. 26, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced financial results for the third quarter of 2021 today. \"Lilly demonstrated strong performance again this quarter.", "url": "https://www.prnewswire.com/news-releases/lilly-reports-robust-third-quarter-2021-financial-results-as-pipeline-success-strengthens-future-growth-potential-301408065.html", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T06:25:00-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 06:31:00", "publisher": "Reuters", "title": "Lilly third quarter profit falls 8% on higher costs", "image": "https://images.financialmodelingprep.com/news/lilly-third-quarter-profit-falls-8-on-higher-costs-20211026.jpg", "site": "reuters.com", "text": "Eli Lilly and Co on Tuesday reported an 8% fall in third quarter profit, reflecting higher research and development costs.", "url": "https://www.reuters.com/article/lilly-results/lilly-third-quarter-profit-falls-8-on-higher-costs-idUSKBN2HG173", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T06:31:00-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 06:50:19", "publisher": "Market Watch", "title": "Eli Lilly & Co. net income falls 8%, but adjusted profit rises", "image": "https://images.financialmodelingprep.com/news/eli-lilly-co-net-income-falls-8-but-adjusted-profit-20211026.jpeg", "site": "marketwatch.com", "text": "Eli Lilly & Co. LLY, +0.53% said Tuesday its third-quarter net income fell 8% to $1.11 billion, or $1.22 a share, from $1.21 billion, or $1.33 a share in the year-ago period. Adjusted net income increased to $1.94 a share from $1.41 a share.", "url": "https://www.marketwatch.com/story/eli-lilly-co-net-income-falls-8-but-adjusted-profit-rises-2021-10-26", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T06:50:19-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 07:27:00", "publisher": "Benzinga", "title": "Eli Lilly: Q3 Earnings Insights", "image": "https://images.financialmodelingprep.com/news/eli-lilly-q3-earnings-insights-20211026.jpeg", "site": "benzinga.com", "text": "Eli Lilly (NYSE:LLY) reported its Q3 earnings results on Tuesday, October 26, 2021 at 06:25 AM. Here's what investors need to know about the announcement.", "url": "https://www.benzinga.com/news/earnings/21/10/23553213/eli-lilly-q3-earnings-insights", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T07:27:00-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 08:02:23", "publisher": "Market Watch", "title": "Lilly plans to run clinical trial comparing its Alzheimer's drug candidate to Biogen's Aduhelm", "image": "https://images.financialmodelingprep.com/news/lilly-plans-to-run-clinical-trial-comparing-its-alzheimers-drug-20211026.jpg", "site": "marketwatch.com", "text": "Shares of Eli Lilly & Co. LLY, +0.53% gained 0.8% in premarket trading on Tuesday after the company told investors as part of its third-quarter earnings that it has started the process to seek approval from the Food and Drug Administration for its experimental Alzheimer's drug, donanemab. It also said it plans to conduct a Phase 3 clinical trial evaluating donanemab against Aduhelm, Biogen Inc.'s BIIB, +1.94% recently approved Alzheimer's drug, to assess \"superiority of brain amyloid plaque clearance in early symptomatic Alzheimer's disease.", "url": "https://www.marketwatch.com/story/lilly-plans-to-run-clinical-trial-comparing-its-alzheimers-drug-candidate-to-biogens-aduhelm-2021-10-26", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T08:02:23-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 08:48:58", "publisher": "Benzinga", "title": "Eli Lilly Q3 Earnings Beat Estimates, Boosts FY21 Guidance On Higher COVID-19 Therapy Sales", "image": "https://images.financialmodelingprep.com/news/eli-lilly-q3-earnings-beat-estimates-boosts-fy21-guidance-20211026.jpg", "site": "benzinga.com", "text": "Eli Lilly And Co (NYSE: LLY) has posted Q3 sales of $6.77 billion, beating the consensus of $5.70 billion and increasing 18% Y/Y. Higher sales were driven by a 17% increase in volume and a 1% increase due to the favorable impact of foreign exchange rates.", "url": "https://www.benzinga.com/general/biotech/21/10/23552810/eli-lilly-q3-earnings-beat-estimates-boosts-fy21-guidance-on-higher-covid-19-therapy-sales", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T08:48:58-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 09:36:19", "publisher": "Invezz", "title": "Eli Lilly CEO defends earnings miss in fiscal Q3", "image": "https://images.financialmodelingprep.com/news/eli-lilly-ceo-defends-earnings-miss-in-fiscal-q3-20211026.jpg", "site": "invezz.com", "text": "Eli Lilly & Co (NYSE: LLY) said its earnings in the fiscal third quarter fell shy of Wall Street estimates. Shares, however, remained stable in premarket trading as revenue came in better-than-expected.", "url": "https://invezz.com/news/2021/10/26/eli-lilly-ceo-defends-earnings-miss-in-fiscal-q3/", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T09:36:19-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 14:14:21", "publisher": "Seeking Alpha", "title": "Eli Lilly and Company (LLY) CEO David Ricks on Q3 2021 Results - Earnings Call Transcript", "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-ceo-david-ricks-on-20211026.jpg", "site": "seekingalpha.com", "text": "Eli Lilly and Company (LLY) CEO David Ricks on Q3 2021 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4462128-eli-lilly-and-company-lly-ceo-david-ricks-on-q3-2021-results-earnings-call-transcript", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T14:14:21-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 15:58:55", "publisher": "Invezz", "title": "Is Eli Lilly or Novartis the better buy after Q3 results?", "image": "https://images.financialmodelingprep.com/news/is-eli-lilly-or-novartis-the-better-buy-after-20211026.jpg", "site": "invezz.com", "text": "On Monday, Eli Lilly And Co (NYSE:LLY) and Novartis AG (OTCMKTS:NVSEF) shares edged higher after announcing their most recent quarterly results. Eli Lilly's revenue and earnings missed expectations while Novartis beat on earnings and matched top-line estimates.", "url": "https://invezz.com/news/2021/10/26/is-eli-lilly-or-novartis-the-better-buy-after-q3-results/", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T15:58:55-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 20:16:36", "publisher": "Seeking Alpha", "title": "Eli Lilly: Quality Wins The Race", "image": "https://images.financialmodelingprep.com/news/eli-lilly-quality-wins-the-race-20211026.jpg", "site": "seekingalpha.com", "text": "Eli Lilly: Quality Wins The Race", "url": "https://seekingalpha.com/article/4462230-eli-lilly-stock-earnings-quality-wins-the-race", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T20:16:36-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-26 21:00:12", "publisher": "The Motley Fool", "title": "Eli Lilly Pitches Alzheimer Drug to the FDA, Aiming to Leapfrog Biogen", "image": "https://images.financialmodelingprep.com/news/eli-lilly-pitches-alzheimer-drug-to-the-fda-aiming-to-20211026.png", "site": "fool.com", "text": "It's an exciting if turbulent, and rather cutthroat, time in the world of Alzheimer's drug research. In June, the FDA greenlit Biogen's.", "url": "https://www.fool.com/investing/2021/10/26/eli-lilly-pitches-alzheimer-drug-to-the-fda-aiming/", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-26T21:00:12-04:00", "date_et": "2021-10-26"}
{"symbol": "LLY", "publishedDate": "2021-10-27 12:58:36", "publisher": "Zacks Investment Research", "title": "Healthcare ETFs in Focus as Q3 Earnings Unfold", "image": "https://images.financialmodelingprep.com/news/healthcare-etfs-in-focus-as-q3-earnings-unfold-20211027.jpg", "site": "zacks.com", "text": "The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.", "url": "https://www.zacks.com/stock/news/1817615/healthcare-etfs-in-focus-as-q3-earnings-unfold", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-27T12:58:36-04:00", "date_et": "2021-10-27"}
{"symbol": "LLY", "publishedDate": "2021-10-28 16:00:00", "publisher": "PRNewsWire", "title": "Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology", "image": "https://images.financialmodelingprep.com/news/additional-verzenio-abemaciclib-phase-3-monarche-trial-data-published-20211028.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Oct. 28, 2021 /PRNewswire/ -- Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib) Phase 3 monarchE study were published in a Letter to the Editor in the Annals of Oncology. These OS data, while immature, have been published to address questions regarding the recent approval by the U.S. Food and Drug Administration (FDA) in a subgroup of the population studied in the monarchE trial.", "url": "https://www.prnewswire.com/news-releases/additional-verzenio-abemaciclib-phase-3-monarche-trial-data-published-in-the-annals-of-oncology-301411243.html", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-10-28T16:00:00-04:00", "date_et": "2021-10-28"}
{"symbol": "LLY", "publishedDate": "2021-11-01 12:00:00", "publisher": "PRNewsWire", "title": "Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference", "image": "https://images.financialmodelingprep.com/news/lilly-to-participate-in-bernsteins-second-annual-operational-decisions-conference-20211101.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Nov. 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021. Jake Van Naarden, CEO of Loxo Oncology at Lilly and president of Lilly Oncology; Mark Mintun, senior vice president, research and development – neuroscience, and president, Avid Radiopharmaceuticals; and Jamie Croaning, global development leader – tirzepatide, will participate in a virtual fireside chat at 12:30 p.m.", "url": "https://www.prnewswire.com/news-releases/lilly-to-participate-in-bernsteins-second-annual-operational-decisions-conference-301412916.html", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-01T12:00:00-04:00", "date_et": "2021-11-01"}
{"symbol": "LLY", "publishedDate": "2021-11-01 21:13:43", "publisher": "Seeking Alpha", "title": "Upcoming Ex-Dividend Dates: November 2-15, 2021", "image": "https://images.financialmodelingprep.com/news/upcoming-exdividend-dates-november-215-2021-20211101.jpg", "site": "seekingalpha.com", "text": "Upcoming Ex-Dividend Dates: November 2-15, 2021", "url": "https://seekingalpha.com/article/4464250-upcoming-ex-dividend-dates-november-2-15-2021", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-01T21:13:43-04:00", "date_et": "2021-11-01"}
{"symbol": "LLY", "publishedDate": "2021-11-02 06:45:00", "publisher": "PRNewsWire", "title": "Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19", "image": "https://images.financialmodelingprep.com/news/lilly-to-supply-614000-additional-doses-of-bamlanivimab-and-20211102.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain individuals.", "url": "https://www.prnewswire.com/news-releases/lilly-to-supply-614-000-additional-doses-of-bamlanivimab-and-etesevimab-to-the-us-government-for-the-treatment-or-post-exposure-prevention-of-covid-19--301413637.html", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-02T06:45:00-04:00", "date_et": "2021-11-02"}
{"symbol": "LLY", "publishedDate": "2021-11-02 15:26:27", "publisher": "GuruFocus", "title": "Eli Lilly's Alzheimer's Drug Could Be 'Game-Changer' for Company", "image": "https://images.financialmodelingprep.com/news/eli-lillys-alzheimers-drug-could-be-gamechanger-for-company-20211102.jpg", "site": "gurufocus.com", "text": "A prominent Wall Street firm thinks Eli Lilly and Co. ( LLY , Financial) hopes to scuttle the introduction of Biogen Inc.'s ( BIIB , Financial) recently approved Alzheimer's drug before it gains traction with its own treatment, according to an article by drug consulting firm Evaluate.", "url": "https://www.gurufocus.com/news/1560474/eli-lillys-alzheimers-drug-could-be-gamechanger-for-company", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-02T15:26:27-04:00", "date_et": "2021-11-02"}
{"symbol": "LLY", "publishedDate": "2021-11-03 13:00:16", "publisher": "Zacks Investment Research", "title": "PFE vs. LLY: Which Stock Should Value Investors Buy Now?", "image": "https://images.financialmodelingprep.com/news/pfe-vs-lly-which-stock-should-value-investors-buy-20211103.jpg", "site": "zacks.com", "text": "PFE vs. LLY: Which Stock Is the Better Value Option?", "url": "https://www.zacks.com/stock/news/1822820/pfe-vs-lly-which-stock-should-value-investors-buy-now", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-03T13:00:16-04:00", "date_et": "2021-11-03"}
{"symbol": "LLY", "publishedDate": "2021-11-04 09:00:00", "publisher": "PRNewsWire", "title": "Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting", "image": "https://images.financialmodelingprep.com/news/loxo-oncology-at-lilly-announces-details-of-presentations-at-20211104.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Nov. 4, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the pirtobrutinib development program at the American Society of Hematology (ASH) Annual Meeting to be held December 11-14, 2021 in Atlanta, GA and virtually. Pirtobrutinib is an investigational, highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor.", "url": "https://www.prnewswire.com/news-releases/loxo-oncology-at-lilly-announces-details-of-presentations-at-the-2021-american-society-of-hematology-ash-annual-meeting-301415328.html", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-04T09:00:00-04:00", "date_et": "2021-11-04"}
{"symbol": "LLY", "publishedDate": "2021-11-05 06:00:27", "publisher": "Forbes", "title": "What's Happening With Eli Lilly Stock?", "image": "https://images.financialmodelingprep.com/news/whats-happening-with-eli-lilly-stock-20211105.jpg", "site": "forbes.com", "text": "The stock price of ​Eli Lilly has seen a rise of 15% over the last month, while it is up 6% in a week. There are a couple of factors that fueled this growth.", "url": "https://www.forbes.com/sites/greatspeculations/2021/11/05/whats-happening-with-eli-lilly-stock/", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-05T06:00:27-04:00", "date_et": "2021-11-05"}
{"symbol": "LLY", "publishedDate": "2021-11-05 15:00:00", "publisher": "PRNewsWire", "title": "Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status", "image": "https://images.financialmodelingprep.com/news/jardiance-shows-consistent-cardiorenal-benefits-in-adults-with-heart-20211105.jpg", "site": "prnewswire.com", "text": "RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 5, 2021 /PRNewswire/ -- Jardiance® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline in adults with heart failure with left ventricular ejection fraction (LVEF) over 40% regardless of chronic kidney disease status at baseline, according to findings from a new prespecified sub-analysis of the EMPEROR-Preserved® phase III trial.", "url": "https://www.prnewswire.com/news-releases/jardiance-shows-consistent-cardio-renal-benefits-in-adults-with-heart-failure-with-left-ventricular-ejection-fraction-over-40-regardless-of-chronic-kidney-disease-status-301417725.html", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-05T15:00:00-04:00", "date_et": "2021-11-05"}
{"symbol": "LLY", "publishedDate": "2021-11-06 04:02:00", "publisher": "Business Wire", "title": "Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status", "image": "https://images.financialmodelingprep.com/news/empagliflozin-shows-consistent-cardiorenal-benefits-in-adults-with-heart-20211106.jpg", "site": "businesswire.com", "text": "INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with LVEF >40 percent regardless of chronic kidney disease status", "url": "https://www.businesswire.com/news/home/20211106005123/en/Empagliflozin-shows-consistent-cardio-renal-benefits-in-adults-with-heart-failure-with-left-ventricular-ejection-fraction-over-40-percent-regardless-of-chronic-kidney-disease-status/", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-06T04:02:00-04:00", "date_et": "2021-11-06"}
{"symbol": "LLY", "publishedDate": "2021-11-07 07:56:05", "publisher": "Seeking Alpha", "title": "V&M Breakouts: Top Growth And Dividend Stocks For November 2021", "image": "https://images.financialmodelingprep.com/news/vm-breakouts-top-growth-and-dividend-stocks-for-november-20211107.jpg", "site": "seekingalpha.com", "text": "Releasing two top November stocks from the MDA Growth and Dividend Breakout monthly portfolio and two top samples from prior portfolios. Long-term dividend portfolios have a 1 year average weighted gain of +20.6%. The best gain is still from the May 2020 portfolio +87.5%.", "url": "https://seekingalpha.com/article/4466695-top-growth-and-dividend-stocks-for-november-2021", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-07T07:56:05-05:00", "date_et": "2021-11-07"}
{"symbol": "LLY", "publishedDate": "2021-11-09 08:30:00", "publisher": "PRNewsWire", "title": "OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis", "image": "https://images.financialmodelingprep.com/news/olumiant-longterm-safety-profile-established-up-to-93-years-20211109.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Nov. 9, 2021 /PRNewswire/ -- OLUMIANT ® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received OLUMIANT for 14,744 patient years of exposure, in line with previously published findings. Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present these results, along with real-world safety results from 3,445 patients with RA in Japan, at ACR Convergence 2021, the American College of Rheumatology's virtual annual meeting taking place November 3-9, 2021.", "url": "https://www.prnewswire.com/news-releases/olumiant-long-term-safety-profile-established-up-to-9-3-years-in-integrated-analysis-of-more-than-3-700-patients-with-rheumatoid-arthritis-301419288.html", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-09T08:30:00-05:00", "date_et": "2021-11-09"}
{"symbol": "LLY", "publishedDate": "2021-11-09 12:47:34", "publisher": "Seeking Alpha", "title": "Upcoming Ex-Dividend Dates: November 10-22, 2021", "image": "https://images.financialmodelingprep.com/news/upcoming-exdividend-dates-november-1022-2021-20211109.jpg", "site": "seekingalpha.com", "text": "Upcoming Ex-Dividend Dates: November 10-22, 2021", "url": "https://seekingalpha.com/article/4467348-upcoming-ex-dividend-dates-november-10-22-2021", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-09T12:47:34-05:00", "date_et": "2021-11-09"}
{"symbol": "LLY", "publishedDate": "2021-11-09 14:00:00", "publisher": "PRNewsWire", "title": "Lilly to Participate in Wolfe Research Virtual Healthcare Conference", "image": "https://images.financialmodelingprep.com/news/lilly-to-participate-in-wolfe-research-virtual-healthcare-conference-20211109.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Nov. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Thursday, Nov. 18, 2021. Jacob Van Naarden, CEO of Loxo Oncology at Lilly and president, Lilly Oncology; Mark Mintun, senior vice president, research and development – neuroscience, and president, Avid Radiopharmaceuticals; and David Hyman, M.D.", "url": "https://www.prnewswire.com/news-releases/lilly-to-participate-in-wolfe-research-virtual-healthcare-conference-301420070.html", "ticker": "LLY", "event_date": "2021-10-26", "window_start": "2021-10-19", "window_end": "2021-11-09", "publishedDateET": "2021-11-09T14:00:00-05:00", "date_et": "2021-11-09"}
